Identification and control of unspecified impurity in trimetazidine dihydrochloride tablet formulation

• Published in: IOP conference series. Materials Science and Engineering Vol. 349; no. 1; pp. 12029 - 12033
• Main Authors: Jefri, Puspitasari, A D, Talpaneni, J S R, Tjandrawinata, R R
• Format: Journal Article
• Language: English
• Published: Bristol IOP Publishing 01.04.2018
• Subjects: Acids; Angina pectoris; Formic acid; High performance liquid chromatography; Impurities; Mass spectrometry; Molecular weight; Pharmacology; Spiking
• ISSN: 1757-8981; 1757-899X
• DOI: 10.1088/1757-899X/349/1/012029

Trimetazidine dihydrochloride is an anti-ischemic metabolic agent which is used as drug for angina pectoris treatment. The drug substance monograph is available in European Pharmacopoeia and British Pharmacopoeia, while the drug product monograph is not available in any of the pharmacopoeias. During development of trimetazidine dihydrochloride tablet formulation, we found increase of an unspecified impurity during preliminary stability study. The unspecified impurity was identified by high performance liquid chromatography coupled with mass spectrometry (LC-MS) and the molecular weight obtained was matching with the molecular weight of N-formyl trimetazidine (m/z 295). Further experiments were performed to confirm the suspected result by injecting the impurity standard and spiking formic acid into the drug substance. The retention time of N-formyl trimetazidine was similar to the unspecified impurity in drug product. Even spiking of formic acid into drug substance showed that the suspected impurity increased with increasing concentration of formic acid. The proposed mechanism of impurity formation is via amidation of piperazine moiety of trimetazidine by formic acid which present as residual solvent in tablet binder used in the formulation. Subsequently, the impurity in our product was controlled by choosing the primary packaging which could minimize the formation of impurity.